Overview

A Study to Investigate the Safety and Effectiveness of Different Doses of Sprifermin in Participants With Osteoarthritis of the Knee

Status:
Completed

Trial end date:
2019-05-07

Target enrollment:

Participant gender:

Summary

This was a multicenter, randomized, double-blind, placebo-controlled, parallel-group Phase 2 trial of Sprifermin administered intra-articularly in participants with primary osteoarthritis of the knee and Kellgren-Lawrence Grade 2 or 3. The trial was intended to investigate the efficacy and safety of different intra articular dosages of Sprifermin in these individuals.

Phase:

Phase 2

Details

Lead Sponsor:

EMD Serono
EMD Serono Research & Development Institute, Inc.

Collaborator:

Nordic Bioscience A/S

Treatments:

Mitogens